Nov 01, 2021
1 mins read
In a new placebo-controlled, randomised, adaptive platform trial, fluvoxamine reduced death and hospital admission in those with COVID-19 by approximately 32%. So does that mean this cheap anti-depressant drug could be used in the fight against SARS-CoV-2 / COVID-19? Well, this video will explain everything you need to know about fluvoxamine.
*CLICK HERE TO WATCH THE FULL VIDEO ON THIS:
BUY ME A COFFEE (Support my research by clicking below):
1.) Fluvoxamine originally received FDA approval in 1994.
2.) Fluvoxamine is in a class of drugs called SSRI's aka selective serotonin re-uptake inhibitors.
3.) Fluvoxamine is traditionally used to treat depression and anxiety.
4.) This drug has 3 major mechanisms of action. Fluvoxamine a.) binds to S1R receptors and reduces cytokine release, b.) reduces circulating histamine, and c.) reduced serotonin uptake by blood platelets.
5.) It is believed that the previously mentioned mechanisms of action help reduce the damaged from active COVID-19 disease.
6.) The name of this clinical trail is called the Together trial and is placebo-controlled, randomised, and adaptive.
7.) Approximately 1500 individuals were given 100 mg 2 X daily of Fluvoxamine for 20 days after being confirmed COVID positive.
8.) Study aimed to see how fluvoxamine would affect those in high risk category with at least 1 comorbid condition.
9.) Patients came from 11 different clinical sites in Brazil.
10.) In the fluvoxamine group, only 79 individuals were admitted to a hospital or transferred to a tertiary medical setting, and 17 died.
11.) In the placebo group, 119 individuals were admitted to a hospital and 25 died.